2 Dividend Stocks Built to Hold Up When Markets Don't

The article highlights Johnson & Johnson and AbbVie as defensive Dividend King candidates amid concerns over Iran-related oil-price pressure, U.S. inflation, and elevated AI spending. J&J is targeting more than $100 billion in annual revenue and pays an annualized dividend of $5.36 per share, yielding 1.9%; AbbVie grew quarterly revenue 10% to more than $16 billion and pays $6.92 per share, yielding 2.7%. AbbVie's Skyrizi and Rinvoq each grew about 24%, helping offset post-exclusivity Humira sales declines.

Analysis

The relevant question is not dividend durability but whether ABBV and JNJ can sustain earnings growth sufficient to prevent their yields from becoming a value-trap signal. ABBV has materially higher operating leverage to successful immunology replacement execution: Skyrizi/Rinvoq must continue to outgrow the Humira erosion curve, while JNJ's more diversified pharma/medtech mix should produce lower volatility but less upside to a simple defensive rotation. In a risk-off tape over days to three months, ABBV's higher carry is likely more attractive; over 6-18 months, JNJ's oncology pipeline and medtech exposure offer cleaner diversification if immunology competition intensifies.

The non-obvious risk is that higher oil-driven inflation raises real-rate sensitivity even for healthcare, compressing multiples on long-duration pipeline value while leaving only near-term cash yield as support. ABBV also faces incremental pressure from biosimilar competition and payer formulary actions across immunology; JNJ's key risk is not cyclical demand but litigation/reserve uncertainty and the execution burden of replacing mature-drug revenue. Neither company should be treated as a direct hedge for an equity drawdown: defensive healthcare historically protects relative performance, but can still decline in an index-led de-risking event.

Consensus likely overstates the signaling value of a multi-decade dividend record. Dividend growth follows cash-flow durability rather than creates it, and both names need earnings revisions to outperform rather than merely provide yield. The cleaner tactical expression is relative: own JNJ against ABBV if immunology data, payer access, or biosimilar commentary deteriorates; own ABBV against JNJ if its replacement-franchise growth remains above expectations and rates stabilize.

Key Decisions for Investors

• Maintain a modest 1-3 month defensive overweight in JNJ versus the S&P 500: use JNJ as lower-beta healthcare exposure, not as a broad-market hedge. Reassess if management lowers full-year pharma or medtech guidance, or if litigation-related reserve disclosures widen materially.
• Initiate ABBV/JNJ relative-value exposure only after the next earnings updates confirm Skyrizi plus Rinvoq growth remains sufficient to offset legacy immunology erosion; target a 5-8% relative move over 3-6 months. Stop out if ABBV's immunology guidance is cut or payer-access commentary weakens.
• Do not chase either name solely on yield following a sharp market selloff. Add only if forward EPS estimates remain stable and the stock's drawdown exceeds the healthcare sector by roughly 5% without an idiosyncratic guidance or regulatory catalyst.
• Watch 10-year real yields and oil-driven inflation prints over the next 1-3 months: a sustained rise in real yields would favor JNJ's steadier near-term cash-flow profile over ABBV's pipeline-duration exposure; falling yields with stable drug-demand data would improve ABBV's multiple-support case.